Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01110473 · ClinicalTrials.gov registry record · Phase 1
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
A Phase 1 study of Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 3
- Study locations
NCT01110473 is a Phase 1 study of Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 52 participants, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01110473, a Phase 1 study of Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated dose of ABT-348 as monotherapy and when given in combination with azacitidine.
Conditions Studied
Interventions
- DRUG ABT-348
- DRUG ABT-348 and azacitidine
Study Locations (3)
Arizona
- Site Reference ID/Investigator# 59324 - Scottsdale
Georgia
- Site Reference ID/Investigator# 26523 - Atlanta
Texas
- Site Reference ID/Investigator# 26522 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01110473
The ClinicalTrials.gov registry entry for NCT01110473 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (86% lower). The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which ABT-348 is the first listed.
NCT01110473 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Georgia, Texas.
Frequently Asked Questions
What is clinical trial NCT01110473 about?
NCT01110473 is a clinical study titled "ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies". The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated dose of ABT-348 as monotherapy and when given in combination with azacitidine.
What is the current status of trial NCT01110473?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2010-04. Estimated completion is 2013-06.
What conditions does trial NCT01110473 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, B-cell Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT01110473?
The interventions under investigation include: ABT-348 (DRUG), ABT-348 and azacitidine (DRUG).
Who is sponsoring clinical trial NCT01110473?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01110473 being conducted?
This trial has 3 study locations across Arizona, Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
RECRUITING · Phase 1
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
RECRUITING · Phase 1
-
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.